PNEUMOCOCCAL CONJUGATE VACCINE, 15 VALENT ADSORBED

Information current as at: 1 August 2026

The processes outlined in the MSW are not applicable to this medicine. Please contact pbs@health.gov.au or 1800 020 613 for further information.

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Vaxneuvance®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: Merck Sharp & Dohme (Australia) Pty Ltd
Condition/indication: (therapeutic use): Prevention of pneumococcal disease
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: New PBS listing (Category 2)
Comment:: --
Other PBAC consideration:: PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE, 15 VALENT ADSORBED

Submission received for:: March 2023 PBAC meeting
Opportunity for consumer comment:: Open 23/11/2022 and close 25/01/2023 (see PBS Website)
PBAC meeting:: Held on 08/03/2023
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: Not Applicable
Lodgement of required documentation:: Not applicable
Agreement to listing arrangements:: Not applicable
Government processes:: Not applicable
Medicine listed on the PBS:: Not applicable

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

Case ID

a663

Page last updated

20 March 2024

v.9.16